An interventional study of initial psycho-oncological contact and Standard in Cancer and Psycho-Oncology, sponsored by Lindenhofgruppe AG. Recruiting at 5 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Lindenhofgruppe AG · Not applicable, Interventional, and Supportive care
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support.
This study investigates whether an initial consultation with a psycho-oncological specialist reduces anxiety and depression, improves quality of life, and whether patients subsequently make greater use of support services.
Participants will be randomised, meaning they will be assigned to groups at random to ensure that the results are comparable. In the intervention group, participants will receive a detailed initial consultation with a psycho-oncology specialist and standard treatment. In the control group, participants receive standard treatment. To gather results, questionnaires are administered at regular intervals (at the start, after 3 and 6 months). The study lasts a total of 6 months.
The study was developed by patients. It is being conducted simultaneously at several hospitals.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 148 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Lindenhofgruppe AG is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the Intervention Arm will be contacted by a psycho-oncological counsellor. The study intervention is a 45 minutes initial psycho-oncological counselling and 3 months follow-up contact.
Other: initial psycho-oncological contact
Participants in the Control Arm will receive current standard of care psycho- oncological support according to local processes.
Other: Standard
initial psycho-oncological contact and 3 months follow-up contact
current standard of care psycho-oncological support according to local processes
Change in anxiety and depression
Change in anxiety and depression from study entry to the 6 months follow-up survey, measured using a summary measure of the entire HADS
Time frame: 6 months follow-up
Change in anxiety and depression components
Change in anxiety and depression components, from study entry to the 6 months follow-up survey, measured using the HADS subscales anxiety / depression
Time frame: 6 months follow-up
Change in quality of life
Change in quality of life, from study entry to the 6 months follow-up survey, measured using a summary measure of the entire EORTC QLQ C30
Time frame: 6 months follow-up
Change in quality-of-life components
Change in quality-of-life components, from study entry to the 6 months follow-up survey, measured using the EORTC QLQ C30 subscales global / functional / symptoms
Time frame: 6 months follow-up
Change in patient's global distress
Change in patient's global distress, from study entry to the 6 months follow-up survey, measured using the distress thermometer
Time frame: 6 months follow-up
Use of psycho-oncological support
Use of psycho-oncological support, measured as quantity of psycho oncological support from study entry to 6 months follow-up
Time frame: 6 months follow-up
Reasons for seeking or not seeking psycho-oncological support
Reasons for seeking or not seeking psycho-oncological support
Time frame: 6 months follow-up
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.
Of 75 industry-sponsored interventional studies with no phase under Neoplasms, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 28 months is above that.
Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lindenhofgruppe AG